Marshall Wace’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $42.1M | Sell |
229,879
-156,049
| -40% | -$28.8M | 0.04% | 426 |
|
|
2025
Q4 | $67.9M | Sell |
385,928
-501,733
| -57% | -$82M | 0.06% | 270 |
|
|
2025
Q3 | $124M | Buy |
887,661
+721,706
| +435% | +$97.6M | 0.13% | 132 |
|
|
2025
Q2 | $20.8M | Buy |
165,955
+160,055
| +2,713% | +$19.9M | 0.02% | 564 |
|
|
2025
Q1 | $807K | Sell |
5,900
-74,052
| -93% | -$10.6M | ﹤0.01% | 1872 |
|
|
2024
Q4 | $12.2M | Buy |
79,952
+13,652
| +21% | +$2.3M | 0.01% | 728 |
|
|
2024
Q3 | $12.9M | Buy |
+66,300
| New | +$13.9M | 0.02% | 666 |
|
|
2024
Q2 | – | Sell |
-23,228
| Closed | -$5.01M | – | 2555 |
|
|
2024
Q1 | $5.01M | Buy |
+23,228
| New | +$5.44M | 0.01% | 998 |
|
|
2023
Q3 | – | Sell |
-5,055
| Closed | -$1.44M | – | 2206 |
|
|
2023
Q2 | $1.44M | Sell |
5,055
-527,878
| -99% | -$157M | ﹤0.01% | 1569 |
|
|
2023
Q1 | $148M | Sell |
532,933
-711,217
| -57% | -$197M | 0.31% | 65 |
|
|
2022
Q4 | $345M | Buy |
1,244,150
+1,093,576
| +726% | +$309M | 0.77% | 8 |
|
|
2022
Q3 | $40.2M | Buy |
150,574
+66,866
| +80% | +$14.2M | 0.09% | 252 |
|
|
2022
Q2 | $17.1M | Sell |
83,708
-34,551
| -29% | -$7.06M | 0.04% | 544 |
|
|
2022
Q1 | $24.9M | Buy |
118,259
+90,805
| +331% | +$19.7M | 0.05% | 416 |
|
|
2021
Q4 | $6.59M | Buy |
27,454
+16,032
| +140% | +$4.12M | 0.01% | 1167 |
|
|
2021
Q3 | $3.23M | Sell |
11,422
-639,898
| -98% | -$210M | 0.01% | 1216 |
|
|
2021
Q2 | $226M | Buy |
651,320
+488,764
| +301% | +$148M | 1.02% | 7 |
|
|
2021
Q1 | $45.5M | Sell |
162,556
-357,297
| -69% | -$96.4M | 0.21% | 93 |
|
|
2020
Q4 | $127M | Buy |
519,853
+403,268
| +346% | +$104M | 0.69% | 22 |
|
|
2020
Q3 | $33.1M | Buy |
116,585
+69,220
| +146% | +$19.3M | 0.21% | 107 |
|
|
2020
Q2 | $12.7M | Sell |
47,365
-16,987
| -26% | -$5.11M | 0.09% | 229 |
|
|
2020
Q1 | $20.4M | Buy |
64,352
+4,630
| +8% | +$1.41M | 0.2% | 108 |
|
|
2019
Q4 | $17.7M | Buy |
59,722
+47,816
| +402% | +$13.3M | 0.12% | 187 |
|
|
2019
Q3 | $2.77M | Hold |
11,906
| – | – | 0.02% | 672 |
|
|
2019
Q2 | $2.78M | Hold |
11,906
| – | – | 0.02% | 674 |
|
|
2019
Q1 | $2.81M | Buy |
11,906
+485
| +4% | +$153K | 0.03% | 644 |
|
|
2018
Q4 | $3.44M | Sell |
11,421
-714
| -6% | -$228K | 0.04% | 571 |
|
|
2018
Q3 | $4.29M | Buy |
+12,135
| New | +$4.18M | 0.04% | 492 |
|
|
2018
Q1 | – | Sell |
-20,356
| Closed | -$6.49M | – | 560 |
|
|
2017
Q4 | $6.49M | Buy |
20,356
+11,946
| +142% | +$3.83M | 0.27% | 82 |
|
|
2017
Q3 | $2.63M | Buy |
8,410
+3,632
| +76% | +$1.08M | 0.12% | 142 |
|
|
2017
Q2 | $1.29M | Buy |
4,778
+1,420
| +42% | +$375K | 0.06% | 162 |
|
|
2017
Q1 | $917K | Sell |
3,358
-85,489
| -96% | -$24.2M | 0.04% | 211 |
|
|
2016
Q4 | $25.2M | Buy |
88,847
+37,313
| +72% | +$11.1M | 0.17% | 157 |
|
|
2016
Q3 | $16.1M | Sell |
51,534
-140,007
| -73% | -$41.5M | 0.11% | 195 |
|
|
2016
Q2 | $46.3M | Buy |
191,541
+179,419
| +1,480% | +$47.3M | 0.39% | 60 |
|
|
2016
Q1 | $3.16M | Sell |
12,122
-189,599
| -94% | -$50.1M | 0.03% | 457 |
|
|
2015
Q4 | $61.8M | Buy |
201,721
+189,356
| +1,531% | +$54.4M | 0.58% | 36 |
|
|
2015
Q3 | $3.61M | Sell |
12,365
-111,494
| -90% | -$36.8M | 0.04% | 348 |
|
|
2015
Q2 | $50M | Buy |
123,859
+47,248
| +62% | +$19M | 0.65% | 30 |
|
|
2015
Q1 | $32.3M | Sell |
76,611
-57,255
| -43% | -$22.6M | 0.42% | 61 |
|
|
2014
Q4 | $45.4M | Buy |
133,866
+120,934
| +935% | +$39.1M | 0.6% | 34 |
|
|
2014
Q3 | $4.28M | Buy |
+12,932
| New | +$4.26M | 0.06% | 310 |
|
Other funds holding BIIB
VCM
VPM
Marshall Wace's BIIB Position: Q1 2026 in Review
Marshall Wace reduced its Biogen (BIIB) stake by 40% in Q1 2026, selling an estimated $28.8M and leaving 229,879 shares worth $42.1M. The position accounts for 0.04% of the portfolio, ranked #426.
Marshall Wace first reported a position in BIIB in Q3 2014 and has held it in 42 quarters since. The position peaked at $345M in Q4 2022. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Marshall Wace held 229,879 shares of Biogen worth $42.1M as of Q1 2026.
- Marshall Wace sold 156,049 Biogen shares in Q1 2026, an estimated $28.8M.
- Biogen made up 0.04% of Marshall Wace's portfolio in Q1 2026, its #426 holding.
- Marshall Wace first reported a position in Biogen in Q3 2014 and has held it in 42 quarters since.
- Marshall Wace's Biogen position peaked at $345M in Q4 2022.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.